Summary
The effect of an oral anti-allergic drug, mequitazine, on the pharmacokinetics of theophylline has been investigated in seven asthmatic patients. They received chronic theophylline therapy (a sustained-release theophylline tablet 200–400 mg b.d. at 12 h intervals) and coadministered mequitazine 6 mg for 3 weeks. Plasma theophylline concentration-time curves and the urinary excretion of theophylline and its major metabolites before and after coadministration of mequitazine were compared.
No significant change in the pharmacokinetic parameters of theophylline or in the urinary recovery of unchanged drug and its metabolites was observed.
Thus, mequitazine did not influence the pharmacokinetics of theophylline and it should be safe for coadministration to asthmatic patients on chronic theophylline therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jenne JW, Wyze E, Rood FS, MacDonald FM (1972) Pharmacokinetics of theophylline: Application to adjustment of the clinical dose of aminophylline. Clin Pharmacol Ther 13: 349–360
Mitenko PA, Ogilvie RI (1973) Rational intravenous doses of theophylline. N Engl J Med 289: 600–603
Levy G, Koysooko R (1975) Pharmacokinetic analysis of the effect of theophylline on pulmonary function in asthmatic children. J Pediatr 86: 789–793
Hendeles L, Bighley L, Richardson RH, Hepler CD, Carmichael J (1977) Frequent toxicity from IV aminophylline infusions in critically ill patients. Drug Intell Clin Pharm 11: 12–18
Yarnell PR, Nai-Shin C (1975) Focal seizures and aminophylline. Neurology 25: 819–822
Burkle WS, Gwizdala CJ (1981) Evaluation of toxic serum theophylline concentrations. Am J Hosp Pharm 38: 1164–1166
Jackson JE, Powell JR, Wandell M, Bentley J, Dorr R (1981) Cimetidine decreases theophylline clearance. Am Rev Respir Dis 123: 615–617
Jonkman JHG, Upton RA (1984) Pharmacokinetic drug interactions with theophylline. Clin Pharmacokinet 9: 309–334
Wijnands WJA, Vree TB, Van Herwaarden CLA (1985) Enoxacin decreases the clearance of theophylline in man. Br J Clin Pharmacol 20: 583–588
Fujimura H, Tsurumi K, Yanagihara M, Hiramatsu Y, Tamura Y, Shimizu Y, Hojo M, Yoshida Y (1981) Pharmacological study of Mequitazine (LM-209) (I) Antagonistic actions of chemical mediators. Folia Pharmacol Jpn 78: 279–289
Ogura Y, Hasegawa T, Yokochi Y, Yamada S, Kitazawa S, Takagi K (1983) Clinical application of substrate-labeled fluorescent immunoassay with antiserum produced using 9-theophylline-BSA immunogen. Jpn J Hosp Pharm 9: 260–266
Muir KT, Jonkman JHG, Tang DD-S, Kuritani M, Riegelman S (1980) Simultaneous determination of theophylline and its major metabolites in urine by reversed-phase ion-pair high-performance liquid chromatography. J Chromatogr 221: 85–95
Tang-Liu DD, Williams RL, Riegelman S (1982) Non-linear theophylline elimination. Clin Pharmacol Ther 31: 358–369
Yasuda K, Tsurumi T, Fujimura H (1986) Study of drug interaction between the new antiallergic drug 11-oxo-11-H-pyrido [2,1-b] quinazoline-2-carboxylic acid and theophylline. Arzneimittelforschung 36: 1642–1646
Takagi K, Kuzuya T, Horiuchi T, Nadai M, Apichartpichean R, Ogura Y, Hasegawa T (1989) Lack of effect of repirinast on the pharmacokinetics of theophylline in asthmatic patients. Eur J Clin Pharmacol 37: 301–303
Matejeck M, Irwin P, Neff G, Abt K, Wehrli W (1985) Determination of the central effects of the asthma prophylactic ketotifen, the bronchodilator theophylline and both in combination. An application of quantitative electroencephalography to the study of drug interaction. Int J Clin Pharmacol Ther Toxicol 23: 258–266
Asamoto H, Kokura M, Kawakami A, Sasaki Y, Fujii H, Sawano N, Ohara Y, Kitamura Y, Morishita H (1988) Effect of azelastine on theophylline clearance in asthma patients. Jpn J Allergol 37: 1033–1037
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hasegawa, T., Takagi, K., Kuzuya, T. et al. Effect of mequitazine on the pharmacokinetics of theophylline in asthmatic patients. Eur J Clin Pharmacol 38, 255–258 (1990). https://doi.org/10.1007/BF00315026
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315026